Table 2.
Long-term hematopoietic outcomes of all non-relapsed study patients
| Years post HSCT | |||||
|---|---|---|---|---|---|
| 1 (N = 357) | 2 (N = 280) | 3 (N = 180) | 4 (N = 131) | 5 (N = 96) | |
| Median hemoglobin—g/L (range) | 129 (10–163) | 130 (76–168) | 134 (79–168) | 132 (79–166) | 133 (91–171) |
| Median platelets—<100 × 109/L (range) | 179 (21–449) | 178 (32–457) | 193 (16–468) | 185 (42–420) | 173 (48–446) |
| Median ANC—×109/L (range) | 3.3 (0.17–10.5) | 3.4 (1–22.6) | 3.4 (1.2–11.1) | 3.1 (1.3–11.2) | 3.3 (0.35–19.2) |
| Poor hematopoietic function*—total no. (%) | 48 (13.4) | 31 (11) | 13 (7.2) | 10 (7.6) | 9 (9.4) |
| Thrombocytopenia—no. | 27 | 16 | 7 | 7 | 4 |
| Anemia—no. | 9 | 11 | 5 | 2 | 3 |
| Neutropenia—no. | 2 | 0 | 0 | 0 | 1 |
| >1 cytopenia—no. | 10 | 4 | 1 | 1 | 1 |
| Poor hematopoietic function* based on CD34+ infusion dose (in ×10 6 cells/kg) | |||||
| 0–2.99—no. (%) | 10/41 (24.4) | 6/33 (18.2) | 1/20 (5) | 3/16 (18.8) | 3/13 (23.1) |
| 3–4.99—no. (%) | 18/116 (15.5) | 9/87 (10.3) | 5/59 (8.5) | 3/47 (6.4) | 3/30 (10) |
| 5–9.99—no. (%) | 17/154 (11) | 14/119 (11.8) | 6/76 (7.9) | 3/50 (6) | 3/35 (8.6) |
| ≥10—no. (%) | 3/46 (6.5) | 2/41 (4.9) | 1/25 (4) | 1/18 (5.5) | 0/18(0) |
HSCT hematopoietic stem cell transplantation
*Poor hematopoietic function was defined as neutropenia (ANC <1 × 109/L), anemia (hemoglobin <100 g/L), or thrombocytopenia (platelets <100 × 109/L)
**The percent of patients with poor hematopoietic function was determined by stratifying patients into categories based on the CD34 dose they were given, and then dividing the number of patients who met the criteria for poor hematopoietic function at each time point by the total number of patients included in the study at that time point who received the same CD34 dose